Thank you so much, Chair.
Thank you for being here today. I'm very excited to be able to ask you some questions.
We have a lot in common, Canada and Australia. An issue I have been exposed to—for the last decade, actually—is the mental health impact on those of our serving members and veterans who were exposed to mefloquine. I notice that, in recommendation 61, you talk specifically about establishing a brain injury program that covers the various sections of the military “and serving and ex-serving members exposed to mefloquine and/or tafenoquine.”
In 61(b), you say, “assess and treat neurocognitive issues affecting serving and ex-serving members, whatever their cause”. Has the Australian government—the Department of Veterans' Affairs—identified, specifically, mefloquine toxicity as a cause in treating mental health and brain stem injuries?